TY - JOUR
T1 - In vivo manipulation of human breast cancer growth by estrogens and growth hormone
T2 - Kinetic and clinical results
AU - Conte, P. F.
AU - Gardin, G.
AU - Pronzato, P.
AU - Miglietta, L.
AU - Rosso, R.
AU - Amadori, D.
AU - Gentilini, P.
AU - Monzeglio, C.
AU - Gallotti, P.
AU - Demicheli, R.
AU - Brema, F.
AU - Sismondi, P.
AU - Miccoli, P.
AU - Lanfranco, C.
AU - Minuto, F.
AU - Barreca, A.
AU - Del Monte, P.
PY - 1990/12/20
Y1 - 1990/12/20
N2 - Since 1983, a series of experimental and clinical studies have been carried out on the possibility of enhancing the chemotherapy effectiveness in breast cancer by expanding the fraction of cycling cells. Theoretically estrogens should recruit breast cancer cells and this fact should result in a higher killing efficiency of antiproliferative drugs. Actually it has been clearly shown, by means of the thymidine labeling index and primer-dependent α-DNA polymerase assay, that low doses of diethylstilbesterol are able to increase the tumor proliferative activity of human breast cancer in vivo (estrogenic recruitment). Three randomized trials have been carried out (one in locally advanced and two in metastatic breast cancer) comparing conventional polichemotherapy vs chemotherapy with estrogenic recruitment. Only limited advantages have been observed in these trials. Searching for new modalities of kinetic manipulation of tumors, recombinant human growth hormone has been employed in a pilot study: the preliminary results indicate that it largely enhances tumor proliferative activity, suggesting the possibility of employing a growth factor system to increase chemosensitivity.
AB - Since 1983, a series of experimental and clinical studies have been carried out on the possibility of enhancing the chemotherapy effectiveness in breast cancer by expanding the fraction of cycling cells. Theoretically estrogens should recruit breast cancer cells and this fact should result in a higher killing efficiency of antiproliferative drugs. Actually it has been clearly shown, by means of the thymidine labeling index and primer-dependent α-DNA polymerase assay, that low doses of diethylstilbesterol are able to increase the tumor proliferative activity of human breast cancer in vivo (estrogenic recruitment). Three randomized trials have been carried out (one in locally advanced and two in metastatic breast cancer) comparing conventional polichemotherapy vs chemotherapy with estrogenic recruitment. Only limited advantages have been observed in these trials. Searching for new modalities of kinetic manipulation of tumors, recombinant human growth hormone has been employed in a pilot study: the preliminary results indicate that it largely enhances tumor proliferative activity, suggesting the possibility of employing a growth factor system to increase chemosensitivity.
UR - http://www.scopus.com/inward/record.url?scp=0025670517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025670517&partnerID=8YFLogxK
U2 - 10.1016/0960-0760(90)90473-X
DO - 10.1016/0960-0760(90)90473-X
M3 - Article
C2 - 1981014
AN - SCOPUS:0025670517
VL - 37
SP - 1103
EP - 1108
JO - Journal of Steroid Biochemistry and Molecular Biology
JF - Journal of Steroid Biochemistry and Molecular Biology
SN - 0960-0760
IS - 6
ER -